一種滅活的新型基因型禽腺病毒4對(duì)最近在中國(guó)出現(xiàn)的雞心包積液綜合征具有保護(hù)作用

2017年8月，中國(guó)農(nóng)業(yè)科學(xué)院哈爾濱獸醫(yī)研究所獸醫(yī)生物技術(shù)國(guó)家重點(diǎn)實(shí)驗(yàn)室；江蘇省重大動(dòng)物傳染病與人畜共患病預(yù)防控制協(xié)同創(chuàng)新中心(State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute of Chinese Academy of Agricultural Sciences, Harbin 150001, China;   Jiangsu Co Innovation Center for Prevention and Control of Important Animal Infectious Disease and Zoonoses, Yangzhou 225009, China) Xiaomei Wang老師研究團(tuán)隊(duì)在《Viruses》上發(fā)表論文：

“An Inactivated Novel Genotype Fowl Adenovirus 4 Protects Chickens against the Hydropericardium Syndrome That Recently Emerged in China”

“一種滅活的新型基因型禽腺病毒4對(duì)最近在中國(guó)出現(xiàn)的雞心包積液綜合征具有保護(hù)作用”

Abstract：

Since 2015, China has experienced outbreaks of severe hydropericardium syndrome (HPS), associated with a novel genotype and hypervirulent fowl adenovirus serotype 4 (FAdV-4) infection, with a prevalence in various provinces of the country. This has resulted in huge economic losses in the poultry industry. The novel FAdV-4 showed new genome characters, such as the natural deletion of open reading frame (ORF) 19 and ORF 27 (1966 bp), and high pathogenicity toward chickens. These are coupled with severe hydropericardium, inclusion body hepatitis, and mortality rates ranging from 30% to 90%. Although several inactivated and subunit vaccines against the traditional FAdV-4 have been developed, no commercial vaccine against the emerged disease caused by the novel strain has been available until now. The potential risks of infection with this novel hypervirulent FAdV-4 urgently require an effective vaccine. Thus, an inactivated oil-emulsion FAdV-4 vaccine formulated with the novel genotype virus was developed in this study. The vaccine provided a high level of antibody, preferential T helper 2 (Th2) (interleukin-4 secretion) not Th1 (interferon-γ secretion) response, and full protection against a lethal dose of the novel hypervirulent FAdV-4. Therefore, the novel genotype FAdV-4 vaccine is proposed as an attractive candidate to prevent and reduce the spread of HPS in the poultry industry of China.

摘要：

自2015年以來(lái)，中國(guó)爆發(fā)了嚴(yán)重心包積液綜合征(HPS)，與一種新型基因型和高毒力禽腺病毒血清型4 (FAdV-4)感染有關(guān)，在全國(guó)多個(gè)省份流行。這給家禽業(yè)造成了巨大的經(jīng)濟(jì)損失。新型FAdV-4具有自然缺失開(kāi)放閱讀框(ORF) 19和ORF 27 (1966 bp)等新的基因組特征，對(duì)雞具有較高的致病性。伴有嚴(yán)重心包積液、包涵體肝炎，死亡率從30%到90%不等。雖然已經(jīng)開(kāi)發(fā)出幾種針對(duì)傳統(tǒng)FAdV-4的滅活疫苗和亞單位疫苗，但迄今為止還沒(méi)有針對(duì)這種新菌株引起的新出現(xiàn)疾病的商業(yè)疫苗。這種新型高毒力FAdV-4感染的潛在風(fēng)險(xiǎn)迫切需要一種有效的疫苗。因此，本研究研制了以新基因型病毒配制的FAdV-4滅活油乳劑疫苗。該疫苗提供了高水平的抗體，優(yōu)先的輔助性T細(xì)胞2 (Th2)(白細(xì)胞介素-4分泌)而不是Th1(干擾素-γ分泌)反應(yīng)，并對(duì)致命劑量的新型高致病性FAdV-4具有充分的保護(hù)作用。因此，新型FAdV-4基因型疫苗被認(rèn)為是預(yù)防和減少HPS在中國(guó)家禽業(yè)傳播的有吸引力的候選疫苗。

該論文中，雞胚細(xì)胞體外培養(yǎng)是使用Ausbian特級(jí)胎牛血清完成的。欲了解或購(gòu)買(mǎi)Ausbian特級(jí)胎牛血清可以聯(lián)系北京締一生物400-166-8600.